Kyprolis Alternatives Compared
Kyprolis (carfilzomib) | Abecma (idecabtagene vicleucel) | Carvykti (ciltacabtagene autoleucel) |
|
---|
Kyprolis (carfilzomib) | Abecma (idecabtagene vicleucel) | Carvykti (ciltacabtagene autoleucel) |
|
|||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Kyprolis is a targeted proteasome inhibitor that may be used to treat multiple myeloma. It is given by infusion either alone or in combination with other medications once or twice weekly by a... View more |
Prescription only
Prescribed for Multiple Myeloma. Abecma may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Multiple Myeloma. Carvykti may also be used for purposes not listed in this medication guide. |
Related suggestions Multiple Myeloma
|
|||||||||||||||||||||||
More about Kyprolis (carfilzomib) | More about Abecma (idecabtagene vicleucel) | More about Carvykti (ciltacabtagene autoleucel) | ||||||||||||||||||||||||
Ratings & Reviews | ||||||||||||||||||||||||||
Kyprolis has an average rating of 5.8 out of 10 from a total of 4 ratings on Drugs.com. 25% of reviewers reported a positive effect, while 25% reported a negative effect. |
Be the first to share your experience with this drug. |
Be the first to share your experience with this drug. |
||||||||||||||||||||||||
Drug Class | ||||||||||||||||||||||||||
Side Effects | ||||||||||||||||||||||||||
Generic Availability | ||||||||||||||||||||||||||
N/A |
N/A |
|||||||||||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Kyprolis prices |
View all Abecma prices |
View all Carvykti prices |
||||||||||||||||||||||||
Dosage Forms Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
Brand Names | ||||||||||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||||||||||
Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
1 hour |
N/A |
N/A |
||||||||||||||||||||||||
CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
Pregnancy Category | ||||||||||||||||||||||||||
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
||||||||||||||||||||||||
Drug Interactions | ||||||||||||||||||||||||||
A total of 340 drugs are known to interact with Kyprolis:
|
A total of 203 drugs are known to interact with Abecma:
|
A total of 203 drugs are known to interact with Carvykti:
|
||||||||||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
Disease Interactions | ||||||||||||||||||||||||||
First Approval Date | ||||||||||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||||||||||
WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||||||||||
More Information | ||||||||||||||||||||||||||
Patient resources | ||||||||||||||||||||||||||
Professional Resources | ||||||||||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.